ライフサイエンスコーパス: analgesics

1 r pain, and medications (eg, anxiolytics and analgesics).

2 fferent opioid and acetaminophen combination analgesics.

3 class of drugs known collectively as opioid analgesics.

4 progress in controlling the abuse of opioid analgesics.

5 ic pain states that are refractive to opioid analgesics.

6 m-guided stepped care approach to optimizing analgesics.

7 heral neurons, are being pursued as possible analgesics.

8 t satisfaction, and use of opioids and other analgesics.

9 hem prime targets for the development of new analgesics.

10 , which is not readily relieved by available analgesics.

11 derlie mechanisms of pain suppression by new analgesics.

12 psis, with animals receiving antibiotics and analgesics.

13 severe pain that needs treatment with opioid analgesics.

14 ght be a novel target for the development of analgesics.

15 egional techniques with opioid and nonopioid analgesics.

16 nagement of drug withdrawal, and as sedative analgesics.

17 ay be a useful new approach to develop novel analgesics.

18 cid (aspirin) is one of the most widely used analgesics.

19 been considered to be promising nonaddictive analgesics.

20 gs such as beta-blockers, antipsychotics and analgesics.

21 e the need for standard postoperative opioid analgesics.

22 cts, accidental poisonings) involving single analgesics.

23 increased the antiallodynic effects of all 3 analgesics.

24 gnificant increase in deaths involving other analgesics.

25 perative pain and consumption of opioids and analgesics.

26 nfront issues related to pain and the use of analgesics.

27 polypeptide antibiotics, preservatives, and analgesics.

28 on of possible substitution effects by other analgesics.

29 agonists represent important targets for new analgesics.

30 analog resiniferatoxin are well known potent analgesics.

31 y for the production of longer acting opioid analgesics.

32 ifferent avenue for the development of novel analgesics.

33 ew decades, few advances have been made with analgesics.

34 ceramide metabolic-to-COX-2 pathway as novel analgesics.

35 more in patients without a regular need for analgesics.

36 muli and, hence, a potential drug target for analgesics.

37 is the principle molecular target of opioid analgesics.

38 nded include an opioid-antagonist and opiate analgesics.

39 s chest pain, which can be managed with oral analgesics.

40 been identified as novel antiepileptics and analgesics.

41 ress in developing new, efficacious and safe analgesics.

42 is the principle molecular target of opioid analgesics.

43 to the development of mu-conotoxins as safe analgesics.

44 e clinical trial designs when developing new analgesics.

45 ated with development of tolerance to opiate analgesics.

46 version of pharmaceuticals, primarily opioid analgesics.

47 To compare the efficacy of 4 oral analgesics.

48 e of analgesics, and one patient had refused analgesics.

49 get for both endogenous and exogenous opioid analgesics.

50 oxynitrite biosynthesis as novel nonnarcotic analgesics.

51 targeting this system hold promise as novel analgesics.

52 e hypnotic response to high levels of opioid analgesics.

53 and cancer pain, suggesting their utility as analgesics.

54 ization phenomena and for in vivo studies as analgesics.

55 or factor in the decision to prescribe these analgesics.

56 receptors have been postulated to be useful analgesics.

57 al use of certain cannabinoids as peripheral analgesics.

58 o significant activity in the field of novel analgesics.

59 rug discovery efforts towards novel visceral analgesics.

60 It remains poorly treated with current analgesics.

61 m-based approaches in the development of new analgesics.

62 ts, antibiotics, diabetes agents, and opioid analgesics.

63 es as safe and potentially abuse-free opioid analgesics.

64 d analgesia and total doses of sedatives and analgesics.

65 2.3 channels as potential targets for opioid analgesics.

66 r syndrome and discharged to be treated with analgesics.

67 tential for the generation of new classes of analgesics.

68 ent selective antagonists of Nav1.7 are weak analgesics.

69 sible for the efficacy of the most effective analgesics.

70 g therapeutic advantage over standard opioid analgesics.

71 er somniferum, is one of the strongest known analgesics.

72 IV reasons for admission: 1) alcohol(s), 2) analgesics, 3) antidepressants, 4) street drugs, 5) seda

73 and reduction or discontinuation of narcotic analgesics (55% of patients), as well as improvements in

74 determining the use of two widely available analgesics (acetaminophen and ibuprofen) in epidemiologi

75 pain measured by pain scores and the need of analgesics after 1 year of surgery.

76 To control for the confounding effects of analgesics, all patients received 650 mg acetaminophen f

77 These include analgesics, anaesthesia required for surgery, and the de

78 Systemic nonopioid analgesics and adjuvant analgesics may be prescribed to

79 essure, invasive cardiopulmonary monitoring, analgesics and aggressive pulmonary hygiene.

80 Multimodal analgesia including nonopioid analgesics and ambulatory continuous peripheral nerve bl

81 t to the clinical community: anticoagulants, analgesics and buffers.

82 misuse and diversion of prescription opioid analgesics and heroin.

83 v) channel inhibitors are used clinically as analgesics and local anesthetics.

84 ts the therapeutic efficacy of morphine-like analgesics and mediates the long duration of kappa opioi

85 nd depression, employment status, and use of analgesics and nonsteroidal anti-inflammatory drugs at 1

86 Treatment of bone pain includes nonsteroidal analgesics and opiates; however, long-term use of these

87 ons for chronic complications include use of analgesics and physical therapy for treatment of avascul

88 pproach to treating knee osteoarthritis with analgesics and physical therapy has not been shown to al

89 pears to affect pain perception, response to analgesics and predisposition for the development of chr

90 diabetic neuropathy is poorly controlled by analgesics and requires high doses of opioids, triggerin

91 ptor agonists may represent a novel class of analgesics and their use in conjunction with morphine wi

92 ople and remains highly resistant to classic analgesics and therapies.

93 ysphoria is key to the development of better analgesics and to defining how the endogenous dynorphin

94 l care practitioners prescribe sedatives and analgesics and, perhaps more broadly, how all medication

95 w-risk factors plus avoidance of nonnarcotic analgesics), and 6 (folic acid supplementation > or = 40

96 reported to occur with the use of sedatives, analgesics, and antipsychotics in the intensive care uni

97 staining treatment and the use of sedatives, analgesics, and nonpharmacologic approaches to easing th

98 on because of persistent pain despite use of analgesics, and one patient had refused analgesics.

99 nnel enhancers were suggested as prospective analgesics, and targeting M channels specifically in per

100 educed during sleep and by sedatives, potent analgesics, and volatile anesthetics.

101 idal antiinflammatory drugs (NSAIDs), simple analgesics, and weak opioids, provide relief in some cas

102 take the form of, for example, antibiotics, analgesics, anti-inflammatories or growth factors.

103 Treatment usually involves analgesics, anti-inflammatory drugs, and supportive care

104 tics, diuretics, beta blockers, anesthetics, analgesics, antiepileptics, antidepressants, and others)

105 Premedication included analgesics, antihistamines, and 5-minute infusions of HM

106 le observed change in deaths involving other analgesics, apart from an increase in oxycodone poisonin

107 Opioid analgesics are commonly used in chronic pain management

108 rption, metabolism, and receptor affinity of analgesics are critical to a drug's efficacy is becoming

109 Topical analgesics are emerging as a valued multimodal analgesic

110 Because opiate analgesics are highly addictive substances, their use in

111 lgesic regimens continues to improve; opioid analgesics are increasingly taking on the role of 'rescu

112 Opioid analgesics are traditionally the treatment for the sever

113 Although opioid analgesics are typically embraced as the mainstay of pha

114 published trial, however, suggests that when analgesics are utilized there may be minimal or no diffe

115 Opioid-based analgesics are widely used for treating chronic pain, bu

116 chnologies to be able to effectively utilize analgesics as part of well designed multimodal regimens

117 Prescription of opioid analgesics at discharge.

118 ,026 (67%) reported having pain or requiring analgesics at initial assessment; of these 2,026 patient

119 This article describes the major opioid analgesics available for the treatment of cancer-related

120 in research and development, the majority of analgesics available to prescribers and patients are bas

121 ch as morphine, are among the most effective analgesics available.

122 postoperatively in pain response or need for analgesics between the study groups.

123 Opiates are potent analgesics but their clinical use is limited by side eff

124 the potential to be effective, nonaddictive analgesics, but their therapeutic utility is greatly lim

125 Opioids are very effective analgesics, but they are also highly addictive.

126 des a rationale for an entirely new class of analgesics by inhibition of oxidative enzyme activity.

127 by increases in prescribing of several other analgesics (co-codamol, paracetamol, codeine, co-dydramo

128 raine attacks has been limited to the use of analgesics, combinations of analgesics with caffeine, er

129 In addition, other analgesics commonly used in the dog were investigated.

130 Opioids remain the most effective analgesics despite their potential adverse effects such

131 mers has the potential to identify leads for analgesics devoid of adverse effects.

132 st functional activity could emerge as novel analgesics devoid of tolerance, dependence, and related

133 e pain is mainly empirical, involving potent analgesics, duct drainage by endoscopic or surgical mean

134 Furthermore, the consumption of analgesics during the postoperative week 1 was assessed.

135 the second week, and greater consumption of analgesics during the second and fourth week.

136 his review will focus on advances in topical analgesics, especially their role as an effective analge

137 Use of analgesics, excluding use within the previous year, was

138 variety of targets for peripherally applied analgesics exists, some of which can be accessed using c

139 d focus on limiting supplies of prescription analgesics for abuse, including ADF technology, efforts

140 morphine and other opioids remain essential analgesics for alleviating pain.

141 The search for new analgesics for arthritis that act on the brain should fo

142 wer adverse events compared with alternative analgesics for cancer pain?

143 abor or postcesarean pain or the response to analgesics for childbirth.

144 Some 25 patients (4.2%) needed occasionally analgesics for chronic groin pain.

145 n conditions may remain responsive to opiate analgesics for extended periods, but such persistent acu

146 l incision or positioning that required oral analgesics for longer than 3-4 days after surgery (five

147 t intratumoral androgen synthesis and act as analgesics for metastatic disease.

148 each of the two treatment groups did not use analgesics for pain control.

149 The prescribing of opioid analgesics for pain management-particularly for manageme

150 ) has continued to be treated primarily with analgesics for pain relief.

151 ciceptor signaling to the brain and serve as analgesics for persistent pain.

152 lated mimetics might serve as a new class of analgesics for preventing and treating neuropathic pain.

153 ds hence represent a promising avenue toward analgesics for the dual treatment of acute and neuropath

154 outcomes of RCT/s comparing 2 or more opioid analgesics for the management of chronic pain were obtai

155 Opioids are effective analgesics for the management of moderate to severe canc

156 ectiveness of morphine and related mu opioid analgesics for the treatment of chronic inflammatory pai

157 pe, which is a target for the development of analgesics for the treatment of chronic neuropathic pain

158 further aid the development of peptide-based analgesics for the treatment of chronic pain.

159 Opioids are the most effective analgesics for the treatment of moderate to severe pain.

160 Hazard ratios (HRs) associated with use of analgesics for total incident hematologic malignancies a

161 COX inhibitors, resolvins may represent new analgesics for treating inflammatory pain.

162 encoded by Oprm1) agonists are the mainstay analgesics for treating moderate to severe pain.

163 ever, 59.6% disagreed with the use of opioid analgesics for treatment of those patients.

164 e increasingly taking on the role of 'rescue analgesics' for acute pain after day-case surgery.

165 o being the target of the potent neuropathic analgesics gabapentin and pregabalin (alpha2delta-1 and

166 of the potential risks and benefits of other analgesics has also followed.

167 alone or in combination with other sedatives/analgesics has become popular for procedural sedation am

168 Frequent use of analgesics has been associated with a higher risk of hea

169 imed at reducing this hyperalgesia (visceral analgesics) has been only partially successful despite p

170 for endogenous opioid neurotransmitters and analgesics, has been a major focus for drug discovery in

171 olatile agents, intravenous anesthetics, and analgesics have all begun to be explored using mostly po

172 While several anaesthetics and analgesics have been reported to alter the incidence and

173 Use and abuse of prescription narcotic analgesics have increased dramatically in the United Sta

174 Use of analgesics (HR, 1.22; 95% CI, 1.08 to 1.37), hypnotics/s

175 HR, 1.35; 95% CI, 1.03 to 1.76); and use of analgesics (HR, 1.33; 95% CI, 1.16 to 1.52), hypnotics/s

176 volved in brain-to-blood transport of opioid analgesics (i.e., morphine).

177 lidine are potent and efficacious non-opioid analgesics in an in vivo model of tonic and persistent p

178 Opioids are the most potent analgesics in clinical use; however, their powerful rewa

179 nto future therapies as antipruritics and/or analgesics in humans.

180 ls for preclinical assessment of prospective analgesics in inflammatory pain states.

181 cted by a lower proportion of patients using analgesics in the fibrin group over the study duration (

182 could contribute to the development of novel analgesics in the future.

183 However, consumption of opioid analgesics in the region is low and data suggest that at

184 and synthesized for potential application as analgesics in various pain states.

185 dequate staffing ratios; and availability of analgesics, including opioids, for pain relief.

186 Prescriptions for opioid analgesics increased substantially from 2002 through 201

187 investigated if exposure of pregnant rats to analgesics (indomethacin or acetaminophen) affected GC d

188 etween 175 and 1,500 nM, similar to those of analgesics intended to block COX enzymes.

189 understanding of the mechanism of action of analgesics, interindividual variations in responses to a

190 Unintentional overdose involving opioid analgesics is a leading cause of injury-related death in

191 Abuse of prescription opioid analgesics is a serious threat to public health, resulti

192 Use of analgesics is common and is associated with increased ri

193 While the therapeutic effect of opioids analgesics is mainly attributed to micro-opioid receptor

194 ased approach to administering sedatives and analgesics is necessary to optimize short- and long-term

195 activate arrestin signaling may be effective analgesics lacking dysphoric effects.

196 sants, beta-blockers, anaesthetic agents and analgesics; length of sedation and analgesia and total d

197 ohol intake up to 10 g/d, use of nonnarcotic analgesics less than once per week, and intake of 400 mi

198 ogenomics and how it affects the response to analgesics, mainly opioids, is presented in this article

199 Systemic nonopioid analgesics and adjuvant analgesics may be prescribed to relieve chronic pain and

200 Moreover, they imply that analgesics may have the unwanted side effect of reducing

201 focused on opioid cessation and alternative analgesics may improve the safety and efficiency of elec

202 We will explore topical analgesics' mechanisms of action and their efficacy as o

203 an alignment-rate, pain-intensity and use of analgesics, no significant differences existed between g

204 ated alkaloids have been described as opioid analgesics, no therapeutically relevant properties of co

205 Opiates are analgesics of choice in the treatment of chronic pain, b

206 of these patients and the effects of opioid analgesics on mu-opioid receptors.

207 Opioid analgesics, once considered the standard approach to pre

208 by use of acute attack therapies (eg, simple analgesics or non-steroidal anti-inflammatory drugs) or

209 amining the associations of over-the-counter analgesics or nonsteroidal anti-inflammatory drugs (NSAI

210 % CI, 1.2 to 3.2), and treatment with opioid analgesics (OR, 1.6; 95% CI, 1.0 to 2.5).

211 CLINICAL QUESTION Do the benefits of opioid analgesics outweigh the risks in patients with persisten

212 e 2005, especially with regard to control of analgesics (overall decrease of 43% since 2005) and hot-

213 and formulations of six prescription opioid analgesics: oxycodone, hydrocodone, hydromorphone, fenta

214 ng or standing and required more intravenous analgesics (P = 0.001, 0.038, and 0.035, respectively).

215 despite significantly less use of peripheral analgesics (P = 0.019).

216 0.02) and took a significantly lower dose of analgesics (P = 0.02).

217 n endocrine disruptor as reported for fellow analgesics paracetamol and aspirin.

218 Secondary outcomes were use of analgesics, perioperative and postoperative complication

219 an attractive target for the development of analgesics, pharmacological proof-of-concept in experime

220 Prescription opioid analgesics play an important role in the treatment of po

221 Currently available analgesics poorly serve individuals suffering from chron

222 Opioid analgesics remain the choice for the treatment of modera

223 Subjects taking analgesics reported slightly higher maximum-pain althoug

224 l catheter combined with systemic multimodal analgesics represents the best combination of safety and

225 s critically ill patients frequently receive analgesics, sedatives, and antipsychotics to optimize pa

226 panied by pharmacologic treatments including analgesics, sedatives, and neuromuscular blockers.

227 The use of analgesics, sedatives, or extubation did not significant

228 for birth gestational age, sex, PMA, dose of analgesics/sedatives (fentanyl, morphine, midazolam), me

229 n and may outweigh the benefits; alternative analgesics should be considered first.

230 Opioid-based analgesics such as buprenorphine and morphine also have

231 Traditional analgesics such as opioids and NSAIDs are also problemat

232 tively modulates the actions of other opioid analgesics, such as fentanyl and methadone.

233 ntinociception.SIGNIFICANCE STATEMENT Opioid analgesics, such as morphine, which target the mu opioid

234 he pain-relieving effects of clinically used analgesics, such as morphine.

235 an enhance analgesia provided by traditional analgesics, such as opiates, and may result in opiate-sp

236 iscovery and development of novel non-opioid analgesics, such as subtype-selective sodium channel blo

237 d that, when controlling for prematurity and analgesics, supportive experiences (e.g., breastfeeding,

238 s impacting the translatability of potential analgesics targeting P2X3 receptors.

239 Analgesics targeting the delta-opioid receptor (DOR) may

240 Intervention participants received more analgesics than the controls across the 12 mo.

241 her and be more willing to administer opioid analgesics than were physicians.

242 r the development of peripherally restricted analgesics that control BTP and improve quality of life

243 promising step in the development of opiate analgesics that distinguish between agonist activity and

244 iew some of the mechanisms and modalities of analgesics that have recently entered into clinical deve

245 receive significant amounts of sedatives and analgesics that increase their risk of developing coma a

246 an efficacious strategy in developing future analgesics that lack abuse potential.

247 The generation of potent opioid analgesics that lack the side effects of traditional opi

248 ndings should stimulate the search for novel analgesics that selectively target this sodium channel s

249 abuse potential compared with current opioid analgesics that target the mu opioid receptor.

250 f acid and U69593 effects to blockade by two analgesics (the nonsteroidal antiinflammatory drug ketop

251 randomization criteria (i.e. need for opioid analgesics) the patient will be randomized to either ear

252 AIDs have been shown to reduce postoperative analgesics, their ability to reduce opioid-related adver

253 synthesis and medicinal use as desensitizing analgesics, their molecular targets remain unknown.

254 utic potential in the use of KOR agonists as analgesics; therefore, it may be beneficial to develop K

255 After discharge, parents recorded all analgesics they gave their child as well as pain scores

256 Toward developing new potential analgesics, this first structure-activity relationship s

257 (SCD), for which patients may require opioid analgesics throughout life.

258 onal modality to compliment other multimodal analgesics to control moderate to severe postoperative p

259 ere between the two extremes in using opioid analgesics to cope with their psychological or spiritual

260 ly ill patients are prescribed sedatives and analgesics to decrease pain and anxiety, improve patient

261 wed the packages of 5 commercially available analgesics to evaluate the prominence and conspicuousnes

262 Opiates have long been used as analgesics to relieve pain associated with various medic

263 erapeutic profile, the search for non-opioid analgesics to replace these well-established therapeutic

264 obstacle for effective delivery of potential analgesics to the brain.

265 y and were more willing to administer opioid analgesics to them than to their demographic counterpart

266 have critiqued their underuse of prescribed analgesics to treat pain in their children after painful

267 s with chronic daily headache and overuse of analgesics, triptans, or other acute headache compounds,

268 ates and exogenous cannabinoids, both potent analgesics used for the treatment of patients with neuro

269 so controlled for the confounding effects of analgesics used to treat NTG-induced headache.

270 ve complications, procedural time, amount of analgesics used, pain intensity until POD 10, duration o

271 e diversion and abuse of prescription opioid analgesics using data through 2013.

272 evelopment of valuable non-narcotic clinical analgesics utilizing cotreatment with ultra-low-dose rol

273 In an attempt to discover novel analgesics, we combined the approach developed to charac

274 To advance the search for novel analgesics, we have generated a panel of monoclonal anti

275 To identify novel NTS2 selective analgesics, we searched for NTS2 selective nonpeptide co

276 Third-line analgesics were scarce across sites and neuropathologies

277 Opioid analgesics were taken by 275 decedents (93.2%), of whom

278 (anticoagulants, diabetes agents, and opioid analgesics) were implicated in an estimated 59.9% (95% C

279 and required a higher dosage of intravenous analgesics when compared with TPLA.

280 Analgesics which affect prostaglandin (PG) pathways are

281 management due to adverse effects of opioid analgesics, which can impede recovery; a problem that is

282 Despite the skilled use of opioid analgesics, which is crucial to the relief of cancer pai

283 and this enhanced pain may be reduced not by analgesics, whose effectiveness is reduced, but by incre

284 rynantheidine analogs show promise as potent analgesics with a mechanism of action that includes mu o

285 or antidepressants and others (e.g., 8c), as analgesics with a reduced side-effect profile.

286 targets, as illustrated by our unique opioid analgesics with a vastly improved pharmacological profil

287 ed to the use of analgesics, combinations of analgesics with caffeine, ergotamines, and the triptans.

288 receptors and suggests an approach to potent analgesics with fewer deleterious side effects.

289 receptor agonists may hold potential as new analgesics with fewer liabilities of use.

290 The search for analgesics with fewer side effects and less abuse potent

291 ng interest in the development of new opioid analgesics with improved therapeutic profiles.

292 In the development of analgesics with mixed-opioid agonist activity, periphera

293 ing evidence of the use of topically applied analgesics with particular reference to day case anaesth

294 ed the promise of these ligands as effective analgesics with reduced liability for adverse effects.

295 arrestin2 might produce improved cannabinoid analgesics with reduced motor suppression.

296 promising lead for the development of opioid analgesics with reduced side effects.

297 promising lead for the development of opioid analgesics with reduced tolerance.

298 vious research has substantiated safe opioid analgesics without abuse liability in primates.

299 ovide a rationale for the development of new analgesics without the side effect profile of broad spec

300 tin, have been proposed to be more effective analgesics, without the adverse effects triggered by the